Oncolytics Historical Cash Flow
| ONCY Stock | USD 0.93 0.02 2.11% |
Analysis of Oncolytics Biotech cash flow over time is an excellent tool to project Oncolytics Biotech future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Other Cashflows From Financing Activities of 742 K or Depreciation of 300.3 K as it is a great indicator of Oncolytics Biotech ability to facilitate future growth, repay debt on time or pay out dividends.
Financial Statement Analysis is much more than just reviewing and examining Oncolytics Biotech latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Oncolytics Biotech is a good buy for the upcoming year.
Oncolytics |
About Oncolytics Cash Flow Analysis
The Cash Flow Statement is a financial statement that shows how changes in Oncolytics balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Oncolytics's non-liquid assets can be easily converted into cash.
Oncolytics Biotech Cash Flow Chart
Add Fundamental
Begin Period Cash Flow
The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.Capital Expenditures
Capital Expenditures are funds used by Oncolytics Biotech to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of Oncolytics Biotech operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.Stock Based Compensation
Compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders.Most accounts from Oncolytics Biotech's cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into Oncolytics Biotech current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Oncolytics Biotech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. For more information on how to buy Oncolytics Stock please use our How to Invest in Oncolytics Biotech guide.At this time, Oncolytics Biotech's Change In Cash is fairly stable compared to the past year. Change In Working Capital is likely to rise to about 1.9 M in 2024, despite the fact that Free Cash Flow is likely to grow to (27 M).
| 2021 | 2022 | 2023 | 2024 (projected) | Capital Expenditures | 285.9K | 55K | 8K | 7.6K | Depreciation | 452.1K | 392K | 403K | 300.3K |
Oncolytics Biotech cash flow statement Correlations
Click cells to compare fundamentals
Oncolytics Biotech Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Oncolytics Biotech cash flow statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change In Cash | 448.1K | 17.1M | 10.0M | (29.6M) | 23.2M | 24.4M | |
| Free Cash Flow | (19.9M) | (22.1M) | (22.7M) | (23.4M) | (28.5M) | (27.0M) | |
| Change In Working Capital | (1.8M) | 209.8K | (908.0K) | 391K | 1.8M | 1.9M | |
| Begin Period Cash Flow | 13.7M | 14.1M | 31.2M | 41.3M | 11.7M | 17.8M | |
| Other Cashflows From Financing Activities | 3.5M | 1.9M | 469.7K | 12K | 781K | 742.0K | |
| Depreciation | 485.6K | 446.2K | 452.1K | 392K | 403K | 300.3K | |
| Capital Expenditures | 10.9K | 29.3K | 285.9K | 55K | 8K | 7.6K | |
| Total Cash From Operating Activities | (19.9M) | (22.1M) | (22.4M) | (23.4M) | (28.4M) | (27.0M) | |
| Net Income | (33.1M) | (22.5M) | (26.3M) | (24.8M) | (27.8M) | (29.1M) | |
| Total Cash From Financing Activities | 21.0M | 39.8M | 33.0M | 12.2M | 32.0M | 18.9M | |
| End Period Cash Flow | 14.1M | 31.2M | 41.3M | 11.7M | 34.9M | 19.4M | |
| Investments | (10.9K) | (29.3K) | (285.9K) | (20.4M) | (122K) | (128.1K) | |
| Total Cashflows From Investing Activities | (10.9K) | (29.3K) | (285.9K) | (20.4M) | (18.4M) | (17.4M) | |
| Change To Account Receivables | (2.0M) | 2.0M | (776.4K) | 345K | 506K | 531.3K | |
| Change To Operating Activities | (1.1M) | (401.1K) | (314.4K) | (1.6M) | (1.5M) | (1.4M) | |
| Change To Netincome | 14.5M | (219.4K) | 4.3M | 697K | 801.6K | 1.1M | |
| Change To Liabilities | 1.3M | (1.4M) | 182.9K | 1.7M | 1.9M | 2.0M | |
| Stock Based Compensation | 1.5M | 2.6M | 3.8M | 2.4M | 2.1M | 1.5M | |
| Other Non Cash Items | 94.8K | 68.5K | 91.7K | (1.7M) | (4.9M) | (4.7M) | |
| Issuance Of Capital Stock | 18.0M | 38.3M | 32.9M | 12.6M | 36.1M | 27.7M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Oncolytics Stock Analysis
When running Oncolytics Biotech's price analysis, check to measure Oncolytics Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Oncolytics Biotech is operating at the current time. Most of Oncolytics Biotech's value examination focuses on studying past and present price action to predict the probability of Oncolytics Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Oncolytics Biotech's price. Additionally, you may evaluate how the addition of Oncolytics Biotech to your portfolios can decrease your overall portfolio volatility.